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Background. Oral poliovirus vaccine (OPV) is less immunogenic in low- or middle-income than in high-income countries. We 
tested whether bacterial and viral components of the intestinal microbiota are associated with this phenomenon.
Methods. We assessed the prevalence of enteropathogens using TaqMan array cards 14 days before and at vaccination in 704 
Indian infants (aged 6–11 months) receiving monovalent type 3 OPV (CTRI/2014/05/004588). Nonpolio enterovirus (NPEV) sero-
types were identified by means of VP1 sequencing. In 120 infants, the prevaccination bacterial microbiota was characterized using 
16S ribosomal RNA sequencing.
Results. We detected 56 NPEV serotypes on the day of vaccination. Concurrent NPEVs were associated with a reduction in OPV 
seroconversion, consistent across species (odds ratio [95% confidence interval], 0.57 [.36–.90], 0.61 [.43–.86], and 0.69 [.41–1.16] 
for species A, B, and C, respectively). Recently acquired enterovirus infections, detected at vaccination but not 14 days earlier, had a 
greater interfering effect on monovalent type 3 OPV seroresponse than did persistent infections, with enterovirus detected at both 
time points (seroconversion in 44 of 127 infants [35%] vs 63 of 129 [49%]; P = .02). The abundance of specific bacterial taxa did not 
differ significantly according to OPV response, although the microbiota was more diverse in nonresponders at the time of vaccination.
Conclusion. Enteric viruses have a greater impact on OPV response than the bacterial microbiota, with recent enterovirus infec-
tions having a greater inhibitory effect than persistent infections.
Keywords. Nonpolio enteroviruses; bacterial microbiota; 16S rRNA; OPV; next generation sequencing.
 
Oral vaccines have consistently proved to be less immunogenic 
in low- and middle-income than in high-income countries [1–3]. 
Several mechanisms may contribute to this phenomenon, in-
cluding maternal (eg, transplacental antibodies), heritable (eg, 
genes determining histo-blood group antigen structure), and 
environmental (eg, enteric pathogen exposure) factors [4]. The 
presence of asymptomatic enteric viruses—particularly nonpolio 
enteroviruses (NPEVs)—has consistently been linked with a re-
duction in the immunogenicity of oral poliovirus vaccine (OPV) 
[5], potentially reflecting competition between viruses at the cel-
lular level [6], activation of innate antiviral immune pathways that 
inhibit OPV replication, or changes in lymphocyte responsiveness 
to poliovirus antigen. Notably, >100 enterovirus serotypes are 
known to infect humans. These can be separated into 4 distinct 
species (A–D) based on the sequence of the VP1 gene (a major 
determinant of antigenicity), of which polioviruses fall within 
species C [7, 8]. However, the relative inhibitory effect of different 
NPEV species or serotypes has not been investigated in any detail.
Other components of the gut microbiota may also be pertinent 
to OPV outcome. Enteric viruses seem to exploit signals from the 
bacterial microbiota when colonizing the intestinal mucosa [9]. 
Among infants in Bangladesh, the abundance of Bifidobacterium 
at the time of OPV administration correlated with poliovirus-spe-
cific immunoglobulin G and CD4+ T-cell responses [10]. However, 
the potential influence of microbiota composition on OPV repli-
cation and neutralizing antibody levels remains uncertain.
During a recent clinical trial in India, the presence of en-
teric viruses (of which the majority were NPEVs) was associ-
ated with reduced seroconversion to monovalent type 3 OPV 
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(mOPV3) [11]. Here, we report on a follow-up study in which 
we tested whether OPV response was associated with specific 
enterovirus serotypes or species, short-term changes in enteric 
virus burden, or bacterial microbiota composition.
METHODS
Study Design
Between 5 August 2014 and 21 March 2015, we carried out 
a randomized, placebo-controlled trial evaluating the effect 
of azithromycin on the immunogenicity of mOPV3 among 
6–11-month-old Indian infants (CTRI/2014/05/004588). The 
protocol and primary outcomes of this study have been pub-
lished elsewhere [11]. Briefly, 754 infants lacking serum neu-
tralizing antibodies to type 3 poliovirus were randomized 1:1 
to receive a 3-day course of oral azithromycin (administered 
once daily at a dose of 10 mg/kg) or placebo, starting 14 days 
before the administration of a single dose of mOPV3. The study 
was approved by the institutional review board of the Christian 
Medical College, Vellore, India, and good clinical practice 
guidelines were followed throughout.
Laboratory Testing and Bioinformatics
Enteropathogen Detection
Stool samples were collected from all infants before treatment 
(day −14) and on the day of vaccination (day 0) and tested for 
the presence of 40 different enteric bacterial, viral, and eukar-
yotic targets using TaqMan array cards (TACs), as described 
elsewhere (Figure 1A) [11]. A cycle threshold (Ct) value of 30 
was used as a universal cutoff for pathogen detection. In all 
day 0 samples that were positive for enteroviruses in the TAC 
assay (targeting the 5’ untranslated region), we carried out a 
semi-nested polymerase chain reaction (PCR) assay targeting 
the VP1 gene [12]. Sanger sequencing of the amplified prod-
ucts was performed with a 3730XL DNA Analyzer, and entero-
virus serotypes were assigned using the RIVM Enterovirus 
Genotyping Tool (version 1.0) [13].
Characterization of the Bacterial Microbiota
We assessed bacterial microbiota composition in 120 infants (60 
per study arm) selected at random from the first 300 trial partic-
ipants. Our laboratory and bioinformatic methods for microbiota 
assessment in this cohort have been published elsewhere [14]. For 
each infant, we included samples collected before treatment (day 
−14) and before vaccination (day 0). We also assessed samples from 
40 adults living with trial participants to provide community-spe-
cific mature microbiota profiles (used as a reference for calculating 
microbiota age). After amplification and sequencing of the 16S ribo-
somal RNA gene V4 region with the Illumina MiSeq system, reads 
were assembled with the FLASH (Fast Length Adjustment of SHort 
reads) CCB, John Hopkins University computational tool, clustered 
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Figure 1. Association between nonpolio enteroviruses (NPEVs) and seroconversion. A, Study design. Circles represent stool samples; square, serum sample. “No.” col-
umn lists numbers of per-protocol infants. B, Enterovirus (EV) serotypes with a prevalence of ≥1%. The diameter of the circle at each branch tip is proportional to serotype 
prevalence. Phylogenetic relationships are as described by Oberste and colleagues [7]. Branch lengths are not proportional to phylogenetic distance. C, Enterovirus prevalence 
by seroconversion status. Error bars indicate 95% confidence intervals. *P < .01; †P < .05. Abbreviations: CV, coxsackievirus; E, echovirus; mOPV3, monovalent type 3 oral 
poliovirus vaccine. 
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de novo into operational taxonomic units (OTUs) using the uclust 
algorithm (implemented with MacQIIME software; version 1.8.0), 
and taxonomically assigned using the RDP classifier.
OPV Outcome
Serum samples collected 21 days after mOPV3 administration 
were tested for neutralizing antibodies against type 3 poliovirus, 
using a modified microneutralization assay with 2-fold serial 
dilutions ranging from 1:4 to 1:512 [15]. Seroconversion was 
defined as the detection of neutralizing antibodies at a dilution 
of ≥1:8. In a subset of 300 infants, shedding of type 3 poliovi-
rus was assessed using real-time PCR in stool samples collected 
7 days after vaccination [16].
Statistical Analysis
Enteropathogen Burden
We included all per-protocol infants with available day 0 TAC 
data in the final analysis (n = 704). The association between each 
enterovirus species and OPV response (seroconversion or shed-
ding as categorical dependent variables) was assessed by means 
of logistic regression. Age and study arm were included as covari-
ates to account for the potential confounding of these variables 
with viral infection status and OPV outcome. We fitted univar-
iate models for each species in turn and multivariate models that 
included all 3 species. Separate models were fitted for individual 
serotypes present in ≥1% of infants. The Fisher exact test was used 
to compare the prevalence of each enterovirus species by study 
arm. To examine whether mixed infections had an additive effect 
on OPV immunogenicity, we assessed the effect of enterovirus 
species count (as a categorical variable) on the odds of serocon-
version. For each species in turn, we also compared the likelihood 
of heterospecific coinfection (≥1 enterovirus of another species) 
in infected versus uninfected infants, using the Fisher exact test.
To test whether the association between infection and OPV 
response varied across enterovirus species, we used the likeli-
hood ratio test (LRT) to compare the fit of logistic regression 
models that only included presence or absence of any entero-
virus with models that included enterovirus species as a catego-
rical variable. Where multiple species were detected, infections 
were classified as “mixed,” and untypeable infections were clas-
sified as “unassigned.”
To examine whether changes in the burden of viral TAC tar-
gets (adenovirus, astrovirus, enterovirus, norovirus, rotavirus, and 
sapovirus) in the 14 days before immunization influenced OPV 
outcome, we classified viruses as absent (not detected on days −14 
or 0), resolved (present on day −14, absent on day 0), recently ac-
quired (absent on day −14, present on day 0), or persistent (present 
on days −14 and 0); these categories are hereafter referred to as 
“infection subclasses.” The impact of infection subclasses on OPV 
response was assessed by means of logistic regression, with age 
and study arm included as covariates. Infection subclasses were in-
cluded if they contained ≥10 infants. We directly compared OPV 
outcome between infants with recently acquired versus persistent 
infections using the Fisher exact test; if a significant discrepancy 
was observed, we assessed whether this was associated with a dif-
ference in pathogen abundance (based on TAC Ct value), using 
the Wilcoxon rank sum test. Analyses were implemented in the 
programming language R [17], and associations with a P value 
<.05 were considered statistically significant.
Microbiota Composition
Among per-protocol infants in the microbiota subset, we com-
pared baseline health and demographic characteristics by serocon-
version status, using the Wilcoxon rank sum test (for continuous 
variables) or the Fisher exact test (for categorical variables). We 
obtained a minimum of 7708 sequences per sample after bioinfor-
matic processing. To standardize sequencing depth, we performed 
analyses using 7500 sequences per sample. Microbiota measures 
of interest included alpha diversity, beta diversity, microbiota sta-
bility, microbiota age, and relative taxon abundance. These were 
compared according to OPV outcome, using the Wilcoxon rank 
sum test (for comparisons of taxon abundance), linear regression 
(for alpha diversity, microbiota stability, and microbiota age), or 
the adonis function (permutation-based analysis of variance; for 
beta diversity), with adjustment for infant age and study arm 
where possible. To account for multiple comparisons, P values 
for relative abundance comparisons were adjusted by Benjamini-
Hochberg false discovery rate correction [18], applied separately at 
each taxonomic rank. The association between alpha diversity and 
enterovirus infection subclass was assessed using linear regres-
sion. We also used the machine-learning Random Forest algo-
rithm to predict OPV outcome based on OTU relative abundance. 
For each model, we carried out 20 cycles of 10-fold cross-valida-
tion using the R package crossval, with 5000 trees per forest. Out-
of-bag error rates and variable importance scores (based on Gini 
impurity) were determined across each of the 200 iterations of 
cross-validation. Sensitivity analyses of alpha and beta diversity 
were carried out, in which azithromycin recipients were excluded.
Data Availability
The 16S ribosomal RNA sequences have been deposited in the 
European Nucleotide Archive (accession No. PRJEB20773). An 
OTU table and relevant metadata have been published else-
where [14].
RESULTS
NPEV Burden
Enteroviruses were present at the time of vaccination (day 0) in 
107 of 367 infants (29%) who seroconverted and 149 of 337 
(44%) who did not (odds ratio [OR], 0.49; 95% confidence in-
terval [CI], .35–.67). Based on partial sequencing of the VP1 
gene, species-level assignments were made in 247 (96%) of the 
256 enterovirus-positive samples and serotype-level assign-
ments were made in 234 (91%). Overall, we detected 56 NPEV 
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serotypes, of which 11 were present in ≥1% of the study pop-
ulation (Figure 1B). Enteroviruses of species A, B, and C were 
detected in 90 (13%), 184 (26%), and 65 (9%) of the infants, 
respectively. Viruses in species D were absent. The receipt of 
azithromycin did not significantly affect the prevalence of any 
enterovirus species (Supplementary Figure  1). Infection with 
multiple enterovirus species was common; 76 of 704 infants 
(11%) harbored 2 species, and 8 of 704 (1%) were harbored 3 
(Supplementary Figure 2). Moreover, the detection of any single 
enterovirus species was a significant risk factor for the presence 
of another (Table 1).
Association Between NPEVs and OPV Response
A negative association between NPEV detection and sero-
conversion to type 3 OPV was observed for each enterovirus 
species (OR [95% CI], 0.59 [.37–.93], 0.62 [.44–.87], and 0.67 
[.40–1.13] for species A, B, and C, respectively, after adjustment 
for age and study arm) (Figure 1C). Although this effect was sig-
nificant only for species A and B, there was no evidence that the 
effect size differed significantly between species (LRT, P = .19). 
The ORs were generally consistent in a multivariate model that 
included all species (Supplementary Table 1), and the presence 
of multiple species did not have an additive inhibitory effect on 
seroconversion (OR [95% CI], 0.45 [.31–.65], 0.67 [.41–1.09], 
and 0.43 [.09–1.80] for infants infected with 1, 2, or 3 species, 
respectively). With the exception of echovirus 14, associations 
between individual serotypes and seroconversion were not 
significant (Supplementary Table  2). Consistent with the data 
for seroconversion status, the association between concurrent 
NPEVs and postvaccination shedding did not vary significantly 
by species (LRT, P = .22) (Supplementary Table 1).
Recently Acquired, Persistent, and Resolved Viruses
To investigate the relationship between recent changes in viral 
infection status and OPV response, we classified viruses as re-
cently acquired, persistent, or resolved (Table 2). Recently ac-
quired enteroviruses were the only infection subclass to be 
significantly associated with OPV response (OR, 0.38; 95% CI, 
.25–.59; P < .001). Notably, the seroconversion rate was signif-
icantly lower among infants with recently acquired as opposed 
to persistent enteroviruses (44 of 127 infants [35%] vs 63 of 129 
[49%]; Fisher test, P = .02). The Ct values for persistent versus 
recently acquired enterovirus infections on day 0 did not dif-
fer significantly (mean Ct [standard deviation], 27.0 [2.2] vs 
27.2 [2.1]; Wilcoxon rank sum test, P = .48), suggesting that the 
difference in immunogenicity between these groups was not 
driven by viral copy number.
The odds of OPV shedding were reduced in infants with 
either recently acquired or persistent enteroviruses on day 0 
(OR [95% CI], 0.55 [.28–1.08] and 0.47 [.25–.91], respectively). 
In contrast to the immunogenicity data, shedding rates did not 
differ significantly between these groups (25 of 53 infants [47%] 
vs 25 of 58 [43%] for recently acquired vs persistent enterovi-
ruses; Fisher test, P >  .99). No other viral infection subclasses 
were significantly associated with vaccine virus shedding 
(Supplementary Table 3).
Association Between Bacterial Microbiota Composition and OPV 
Response
Of the 120 infants included in the microbiota subset, 114 (95%) 
completed the study per protocol. The effects of azithromycin on 
microbiota composition in these infants, including a reduction in 
the abundance of Proteobacteria and Verrucomicrobia, have been 
reported elsewhere [14]. Baseline health and socio-demographic 
characteristics were generally comparable between OPV respond-
ers and nonresponders in the microbiota subset (Supplementary 
Table  4), although failure to seroconvert was associated with a 
lower height-for-age z score at enrollment (day −14)—a discrep-
ancy not apparent in the trial population as a whole [11].
We did not observe a strong correlation between composi-
tion of the bacterial microbiota at the time of vaccination (day 
0) and OPV immunogenicity (Figure 2 and Table 3). UniFrac 
distance from adults (an indicator of microbiota age) was 
lower in nonresponders compared with responders (Table  3), 
whereas seroconversion status accounted for a significant but 
small proportion of variance among samples based on UniFrac 
distances (adonis function, P  =  .03; R2  =  0.013) (Table  3 and 
Figure 2C). We did not observe significant differences in OTU 
count, Shannon index, microbiota stability, or relative taxon 
abundances according to seroconversion status (Table  3 and 
Figure 2B). Random Forest models based on OTU abundance 
data failed to accurately distinguish infants according to OPV 
outcome (Figure 2D).
Similar results were obtained when comparing individuals 
according to vaccine shedding status (Table 3). In contrast to 
the immunogenicity data, however, OTU count and Shannon 
index were significantly higher among nonshedders than shed-
ders, and the class  Clostridia was enriched in nonshedders 
(mean relative abundance [standard deviation], 11.6% [10.2%] 
vs 5.65 [7.7%]; Wilcoxon rank sum test corrected for false dis-
covery rate, P = .04) (Supplementary Table 5). Neither the OTU 
count nor the Shannon index varied significantly according to 
Table 1. Co-occurrence of Enterovirus Species
Enterovirus Subset
Prevalence of ≥1 Heterotypic 
Enterovirus, Number of 
Infants /  Total (%)a
Species A positive 59/90 (65.6)
Species A negative 157/614 (25.6)
Species B positive 65/184 (35.3)
Species B negative 63/520 (12.1)
Species C positive 52/65 (80.0)
Species C negative 182/639 (28.5)
aP < .001 for all comparisons (Fisher exact test). 
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enterovirus infection subclass (LRT, P > .05) (Supplementary 
Figure 3), suggesting that the observed discrepancies in alpha 
diversity according to OPV outcome were not related to NPEV 
infection.
We observed no significant differences in microbiota com-
position according to OPV outcome in baseline (day −14) sam-
ples (Supplementary Table 6). Moreover, the primary outcomes 
were largely unaffected when infants in the azithromycin arm 
were excluded (Supplementary Table 6).
DISCUSSION
The notion that concurrent enteroviruses may interfere with 
OPV immunogenicity dates back to the earliest trials of this 
vaccine [5]. Aside from a handful of relatively small associa-
tion studies [19, 20], however, the extent to which this effect 
varies among enterovirus species or serotypes has not been 
tested. In a large cohort of Indian infants who received a single 
dose of mOPV3, we observed a significant inhibitory effect of 
concurrent NPEVs on OPV response. Moreover, we found this 
effect to be consistent across enterovirus species and enhanced 
when infection with these viruses was recently acquired.
The current study is among the first to characterize NPEV 
burden in asymptomatic infants living in a low- or middle-in-
come country. Our findings highlight not only the high preva-
lence of NPEVs in this setting (35%) but also their considerable 
diversity. We observed a total of 56 different NPEV serotypes, 
of which coxsackievirus A6—one of the major serotypes impli-
cated in clinical conditions such as hand, foot, and mouth dis-
ease [21]—was the most common. Two or more enterovirus 
species were detected in 11% of infants, and the presence of 
any single species was associated with an increased likelihood 
of heterospecific coinfection, suggesting that shared risk factors 
(eg, poor sanitation and hygiene) prompt multiple NPEV expo-
sures. Several previous studies have used cell culture to char-
acterize the burden of NPEVs among children presenting with 
acute flaccid paralysis. For example, NPEVs were documented 
Table 2. Association Between Viral Infection Subclasses and OPV3 Seroconversiona
Infection Status by 
Pathogen Infants, No.
Seropositive Infants,
No. (%) OR (95% CI) P Value
P Value (Recently 
Acquired vs Persistent) 
Adenovirus
 Absent 507 269 (53.1) … … …
 Resolved 74 45 (60.8) 1.36 (.83–2.27) .23 …
 Recently acquired 88 40 (45.5) 0.73 (.46–1.16) .19 …
 Persistent 35 13 (37.1) 0.53 (.26–1.07) .08 .43
Astrovirus
 Absent 684 355 (51.9) … … …
 Resolved 10 5 (50.0) 1.10 (.30–4.05) .89 …
 Recently acquired 10 7 (70.0) 2.30 (.58–10.81) .24 …
 Persistent 0 … … … …
Enterovirus
 Absent 313 178 (56.9) … … …
 Resolved 135 82 (60.7) 1.24 (.82–1.90) .30 …
 Recently acquired 127 44 (34.6) 0.38 (.25–.59) <.001 …
 Persistent 129 63 (48.8) 0.70 (.46–1.06) .09 .02
Norovirus
 Absent 604 318 (52.6) … … …
 Resolved 39 22 (56.4) 1.18 (.61–2.32) .62 …
 Recently acquired 46 20 (43.5) 0.70 (.38–1.28) .25 …
 Persistent 15 7 (46.7) 0.67 (.23–1.89) .44 >.99
Rotavirus
 Absent 685 362 (52.8) … … …
 Resolved 6 2 (33.3) … … …
 Recently acquired 12 3 (25.0) 0.34 (.07–1.16) .11 …
 Persistent 1 0 (0.0) … … …
Sapovirus
 Absent 671 348 (51.9) … … …
 Resolved 15 8 (53.3) 1.11 (.39–3.23) .84 …
 Recently acquired 16 9 (56.2) 1.30 (.47–3.7) .62 …
 Persistent 2 2 (100.0) … … …
Abbreviations: CI, confidence interval; OPV3, type 3 oral poliovirus vaccine; OR, odds ratio.
aAge and study arm were included as covariates in all logistic regression models. 
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in 15% of cases in West Africa [22] and 19% in southwestern 
India [23]. The higher prevalence of NPEVs reported here 
among asymptomatic infants may reflect the enhanced sensitiv-
ity of PCR-based versus culture-based detection methods [24].
Of the 56 NPEV serotypes observed in this population, 45 
were present in <1% of infants, limiting our capacity to com-
pare the effect of individual serotypes on OPV. The consistent 
species-level associations suggest that evolutionary (and anti-
genic) distance from poliovirus—a species C enterovirus—does 
not influence the outcomes of concurrent infection. Likewise, 
in cell culture, numerous NPEV serotypes have been shown 
to interfere with poliovirus replication [6]. Notably, enterovi-
ruses exhibit long-term cycles in transmission that vary across 
serotypes; whereas some strains show regular annual peaks, 
others cause epidemics once every few years [25]. Our study 
was performed between August and March—a period typi-
cally associated with reduced NPEV transmission across India 
[26]. It is possible that distinct serotype-specific effects on OPV 
will only be apparent in particular seasons or years. Crucially, 
our findings are consistent with reports of seasonal variation 
in OPV immunogenicity [26] and suggest that planning OPV 
campaigns at times of year when enterovirus transmission is 
low may improve vaccine response.
By considering the viral infection burden at multiple time 
points before vaccination, we observed a reduction in OPV 
immunogenicity in infants with newly acquired as opposed to 
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persistent enterovirus infections. This finding should be inter-
preted with caution, given its modest effect size and the fact that 
we did not find this discrepancy when considering OPV shed-
ding. Nonetheless, it is plausible that recently acquired viruses 
may have an enhanced inhibitory effect on OPV response. Viral 
infections initiate a cascade of innate immune effectors that 
typically peak within several days of exposure [27]. Meanwhile, 
enteroviruses interfere with protein synthesis and secretion 
pathways to repress host interferon responses [28]. If the in-
duction of innate antiviral immunity is responsible for the in-
hibitory effect of enteroviruses on OPV, the greater effect of 
recently acquired NPEVs compared with persistent infections 
could be due to the waning and/or repression of innate antiviral 
responses over time.
Intestinal viruses other than enteroviruses may also inter-
fere with OPV. During the primary analysis of this cohort, 
rotaviruses and adenoviruses were associated with a reduction 
in OPV immunogenicity [11]. The same trends were evident 
here; however, the statistical power of individual comparisons 
was reduced by the distinction between persistent and recently 
acquired infection subclasses. Despite the potential inhibitory 
effect of other viruses, the considerably higher prevalence of 
enteroviruses ensures that this genus is likely to account for a 
much greater fraction of OPV failure.
In addition to the effect of intestinal viruses, dysbiosis of 
the bacterial microbiota has been proposed as a possible cause 
of impaired oral vaccine performance in low- or middle-in-
come countries [29, 30]. Although lacking a consistent defi-
nition, dysbiosis has typically been linked with a reduction in 
microbiota diversity and a detectable shift (or “perturbation”) 
in overall composition [31]. In the current study, microbiota 
diversity was negatively correlated with OPV shedding. Given 
the modest effect size of the observed discrepancies and the 
fact that several previous studies have observed no such corre-
lation [10, 32, 33], it seems unlikely that increased microbiota 
diversity represents a significant risk factor for vaccine failure, 
Table 3. Association Between Bacterial Microbiota Comparison at the Time of Vaccination (Day 0) and Oral Poliovirus Vaccine Response
Comparison Test
Age/Arm as 
Covariates
Seroconversion Shedding
Seropositive
(n = 62)a
Seronegative
(n = 52) P Value
Shedders
(n = 42)
Nonshedders
(n = 33) P Value
Alpha diversity
 OTU count, mean 
(SD)
LR Yes 68.8 (14.1) 73.4 (15.3) .20 65.4 (14.5) 72.0 (16.4) .03
 Shannon index, 
mean (SD)
LR Yes 2.62 (0.47) 2.82 (0.55) .08 2.57 (0.50) 2.84 (0.59) .03
Beta diversity
 UniFrac distance 
between samples
Adonis 
function
Yes R2 = 0.013 .04 R2 = 0.025 .007
Microbiota age, 
mean (SD), 
UniFrac distance 
from samples col-
lected from nonco-
habiting adults
LR Yes 0.833 (0.042) 0.811 (0.050) .01 0.838 (0.046) 0.806 (0.052) .001
Microbiota stabil-
ity, mean (SD), 
UniFrac distance 
between d 0 and 
d–14
LR Yes 0.470 (0.071) 0.460 (0.085) .70 0.476 (0.078) 0.455 (0.088) .20
Taxon abundance: 
phylum-, class-, 
genus-, and 
OTU-level relative 
abundance
WRS Nob No discrepancies with FDR P < .15 Clostridia enriched in nonsheddersc
Cross-validation ac-
curacy for Random 
Forest algorithm, 
median (IQR; 
baselined), %
… Nob 54.5 (45.5–63.6; 54.5) 62.5 (50.0–75.0; 56.0)
Abbreviations: FDR, adjusted for false discovery rate; IQR, interquartile range; LR, linear regression; OTUs, operational taxonomic units; SD, standard deviation; WRS, Wilcoxon rank sum 
test. 
aA total of 120 infants were included in the microbiota subset, of whom 114 completed the study per protocol and were included in the final analyses. 
bAlthough age and study arm could be included as covariates when applying linear regression or the adonis function, it was not possible to adjust for these variables when applying the WRS 
test (a nonparametric test) or the Random Forest algorithm. 
cSee Supplementary Table 5 for full results.
dExpected accuracy if all individuals are assigned to the majority class.
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although it may be a marker for exposure to enteric infections. 
Other discrepancies in microbiota composition with respect 
to OPV response were modest, as exemplified by the inability 
of the Random Forest algorithm to accurately distinguish 
responders from nonresponders based on OTU abundance 
data. Thus, nonresponders did not exhibit any clear manifesta-
tions of microbiota dysbiosis.
Several other studies have looked at the possible effect of the 
bacterial microbiota on oral vaccine outcome. Among infants 
in Bangladesh, OPV response was positively correlated with 
Bifidobacterium abundance [10]. In Ghana, oral rotavirus vac-
cine immunogenicity was associated with an increased abun-
dance of Streptococcus bovis and decreased abundance of the 
phylum Bacteroidetes [32], although no such discrepancies were 
apparent during a rotavirus vaccine study in Vellore, India [33]. 
In the current study, we did not identify any OTUs or genera 
that were significantly associated with OPV response. Although 
abundance of the class  Clostridia was negatively correlated 
with vaccine shedding, given that older infants were less likely 
to respond to OPV [11], the observed discrepancy probably 
reflects the confounding of Clostridia abundance with age [14]. 
Differences in infant age, vaccine, laboratory methods, trial set-
ting, and immunogenicity measure may all have contributed to 
the discrepancies in findings among studies reporting on the 
association between bacterial microbiota composition and oral 
vaccine response. For now, reproducible signatures of oral vac-
cine failure within the bacterial microbiota remain elusive.
Our study has several limitations. Biases in amplification effi-
ciency may have undermined our characterization of the bacte-
rial microbiota [34], and a focus on relative rather than absolute 
taxon abundance (accounting for variation in total microbial 
load) may have obscured potentially relevant associations [14, 
35]. By applying a Ct cutoff of 30 for pathogen targets during 
the TAC assays, we may have failed to characterize the effect 
of enteric viruses present at low abundance. Finally, during our 
analysis of infection subclasses, it is possible that the replace-
ment of one virus with another would be mistakenly categorized 
as a persistent infection, because we did not determine entero-
virus serotype in samples collected 14 days before vaccination.
In conclusion, we did not observe any signs of bacterial mi-
crobiota dysbiosis among infants in India who failed to respond 
to mOPV3. The presence of NPEVs was associated with a lower 
response to OPV that was consistent across enterovirus species, 
and recently acquired enteroviruses seemed to inhibit OPV im-
munogenicity more than persistent infections. Although these 
findings do not preclude a role for more entrenched risk factors 
of OPV failure, such as the chronic inflammation associated 
with environmental enteropathy, they suggest that the likeli-
hood of responding to OPV may fluctuate from week to week 
and are consistent with seasonal trends in OPV immunoge-
nicity that may reflect the abundance of NPEVs.
Notes
Author contributions. I. P., MD; N. C. G., D Phil and G. 
K., MD, PhD had full access to all the data in the study and 
had final responsibility for the decision to submit for publica-
tion. I. P., E. P. K. P., N. C. G., B. K., and G. K. conceived the 
study. S. P. K., J. H. P. and J. J. managed the clinical trial. I. P., 
E. P. K. P., S. G., D. J. A. , S. S., M. I-G., R. R., and G. K. led the 
laboratory work. I. P., E. P. K. P., and N. C. G. led the statistical 
analysis. All authors contributed to the interpretation of the 
data, writing of the report, and approved the final manuscript.
Acknowledgments. We are grateful to Margarita Pons-
Salort for providing valuable comments on the manuscript.
Disclaimer. The views expressed are those of the authors 
and do not necessarily represent those of the National Institute 
for Health Research or Public Health England. The funder had 
no role in the study design, data collection, data analysis, data 
interpretation, or writing of the report. 
Financial support. This study was funded by the Bill and 
Melinda Gates Foundation (grant OPP1039135 to N. C. G. and 
G. K.).
Potential conflicts of interests. M. I. G. received support from 
an Institutional Strategic Support Fund Wellcome Trust grant 
awarded to the University of Liverpool and the Health Protection 
Research Unit in Gastrointestinal Infections, National Institute 
for Health Research at the University of Liverpool (grant NIHR 
HPRU 2012-10038). All other authors report no potential con-
flicts. All authors have submitted the ICMJE Form for Disclosure 
of Potential Conflicts of Interest. Conflicts that the editors consider 
relevant to the content of the manuscript have been disclosed.
References
 1. Patriarca PA, Wright PF, John TJ. Factors affecting the im-
munogenicity of oral poliovirus vaccine in developing 
countries: review. Rev Infect Dis 1991; 13:926–39.
 2. Madhi SA, Cunliffe NA, Steele D, et  al. Effect of human 
rotavirus vaccine on severe diarrhea in African infants. N 
Engl J Med 2010; 362:289–98.
 3. Suharyono SC, Witham N, Punjabi N, et  al. Safety and 
immunogenicity of single-dose live oral cholera vaccine 
CVD 103-HgR in 5–9 year old Indonesian children. Lancet 
1992; 340:689–94.
 4. Parker EP, Ramani S, Lopman BA, et  al. Causes of im-
paired oral vaccine efficacy in developing countries. Future 
Microbiol 2018; 13:97–118.
 5. Parker EP, Kampmann B, Kang G, Grassly NC. Influence of en-
teric infections on response to oral poliovirus vaccine: a system-
atic review and meta-analysis. J Infect Dis 2014; 210:853–64.
 6. Hsiung GD. Multiplication of poliovirus in tissue cultures 
previously infected with other enteroviruses. Arch Gesamte 
Virusforsch 1961; 11:343–54.
1186 • JID 2019:219 (15 April) • Praharaj et al
 7. Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. 
Molecular evolution of the human enteroviruses: correla-
tion of serotype with VP1 sequence and application to pi-
cornavirus classification. J Virol 1999; 73:1941–8.
 8. Pons-Salort M, Parker EP, Grassly NC. The epidemiology of 
non-polio enteroviruses: recent advances and outstanding 
questions. Curr Opin Infect Dis 2015; 28:479–87.
 9. Kuss SK, Best GT, Etheredge CA, et al. Intestinal microbiota 
promote enteric virus replication and systemic pathogen-
esis. Science 2011; 334:249–52.
 10. Huda MN, Lewis Z, Kalanetra KM, et al. Stool microbiota and 
vaccine responses of infants. Pediatrics 2014; 134:e362–72.
 11. Grassly NC, Praharaj I, Babji S, et al. The effect of azithro-
mycin on the immunogenicity of oral poliovirus vaccine: a 
double-blind randomised placebo-controlled trial in sero-
negative Indian infants. Lancet Infect Dis 2016; 16:905–14.
 12. Iturriza-Gómara M, Megson B, Gray J. Molecular detection 
and characterization of human enteroviruses directly from 
clinical samples using RT-PCR and DNA sequencing. J Med 
Virol 2006; 78:243–53.
 13. Kroneman A, Vennema H, Deforche K, et al. An automated 
genotyping tool for enteroviruses and noroviruses. J Clin 
Virol 2011; 51:121–5.
 14. Parker EPK, Praharaj I, John J, et al. Changes in the intes-
tinal microbiota following the administration of azithromy-
cin in a randomised placebo-controlled trial among infants 
in south India. Sci Rep 2017; 7:9168.
 15. World Health Organization. Manual of laboratory meth-
ods for testing of vaccines used in the WHO Expanded 
Programme. WHO/VSQ/9704. Geneva, Switzerland: World 
Health Organization, 1997.
 16. Giri S, Rajan AK, Kumar N, et al. Comparison of culture, 
single and multiplex real-time PCR for detection of Sabin 
poliovirus shedding in recently vaccinated Indian children. 
J Med Virol 2017; 89:486–8. 
 17. R Development Core Team. R: a language and environment 
for statistical computing. Vienna, Austria: R Foundation for 
Statistical Computing, 2010.
 18. Benjamini Y, Hochberg Y. Controlling the false discovery 
rate: a practical and powerful approach to multiple testing. 
J R Statist Soc B 1995; 57:289–300.
 19. Fang-Cho K. Serologic response in children of 0 to 7 years 
of age to oral administration of Sabin live poliomyelitis vac-
cine. In: Oral live poliovirus vaccine: papers presented at the 
IVth Scientific Conference of the Institute of Poliomyelitis 
and Virus Encephalitis and the International Symposium 
on Live Poliovirus Vaccine. Moscow: Moscow Academy of 
Medical Sciences of the USSR, 1960: 261–6.
 20. John TJ, Christopher S. Oral polio vaccination of children 
in the tropics. III. Intercurrent enterovirus infections, vac-
cine virus take and antibody response. Am J Epidemiol 
1975; 102:422–8.
 21. Bian L, Wang Y, Yao X, Mao Q, Xu M, Liang Z. Coxsackievirus 
A6: a new emerging pathogen causing hand, foot and 
mouth disease outbreaks worldwide. Expert Rev Anti Infect 
Ther 2015; 13:1061–71.
 22. Fernandez-Garcia MD, Kebe O, Fall AD, Ndiaye K. 
Identification and molecular characterization of non-polio 
enteroviruses from children with acute flaccid paralysis in 
West Africa, 2013–2014. Sci Rep 2017; 7:3808.
 23. Laxmivandana R, Yergolkar P, Gopalkrishna V, Chitambar 
SD. Characterization of the non-polio enterovirus infec-
tions associated with acute flaccid paralysis in South-
Western India. PLoS One 2013; 8:e61650.
 24. Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, 
Tatem JM. Direct detection of Sabin poliovirus vaccine strains 
in stool specimens of first-dose vaccinees by a sensitive reverse 
transcription-PCR method. J Clin Microbiol 1999; 37:283–9.
 25. Khetsuriani N, Lamonte-Fowlkes A, Oberste S, Pallansch 
MA; Centers for Disease Control and Prevention. 
Enterovirus surveillance—United States, 1970–2005. 
MMWR Surveill Summ 2006; 55:1–20.
 26. Grassly NC, Jafari H, Bahl S, et al. Waning intestinal immu-
nity after vaccination with oral poliovirus vaccines in India. 
J Infect Dis 2012; 205:1554–61.
 27. Duan G, Yang H, Shi L, et al. Serum inflammatory cytokine 
levels correlate with hand-foot-mouth disease severity: a 
nested serial case-control study. PLoS One 2014; 9:e112676.
 28. Lu J, Yi L, Ke C, et  al. The interaction between human 
enteroviruses and type I  IFN signaling pathway. Crit Rev 
Microbiol 2015; 41:201–7.
 29. Levine MM. Immunogenicity and efficacy of oral vaccines 
in developing countries: lessons from a live cholera vaccine. 
BMC Biol 2010; 8:129.
 30. Valdez Y, Brown EM, Finlay BB. Influence of the microbiota 
on vaccine effectiveness. Trends Immunol 2014; 35:526–37.
 31. Walters WA, Xu Z, Knight R. Meta-analyses of human gut 
microbes associated with obesity and IBD. FEBS Lett 2014; 
588:4223–33.
 32. Harris VC, Armah G, Fuentes S, et  al. Significant cor-
relation between the infant gut microbiome and rota-
virus vaccine response in rural Ghana. J Infect Dis 2017; 
215:34–41.
 33. Parker EPK, Praharaj I, Zekavati A, et al. Influence of the 
intestinal microbiota on the immunogenicity of oral rota-
virus vaccine given to infants in south India. Vaccine 2018; 
36:264–72.
 34. D’Amore R, Ijaz UZ, Schirmer M, et  al. A comprehensive 
benchmarking study of protocols and sequencing platforms 
for 16S rRNA community profiling. BMC Genomics 2016; 
17:55.
 35. Vandeputte D, Kathagen G, D’hoe K, et al. Quantitative 
microbiome profiling links gut community variation to 
microbial load. Nature 2017; 551:507–11.
